Table of Contents Author Guidelines Submit a Manuscript
Veterinary Medicine International
Volume 2011, Article ID 487592, 5 pages
http://dx.doi.org/10.4061/2011/487592
Research Article

An Investigation Comparing the Efficacy of Topical Ocular Application of Tacrolimus and Cyclosporine in Dogs

1Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, 2407 River Drive, Knoxville, TN 37996, USA
2The Hope Center for Advanced Veterinary Medicine, Vienna, VA 22180, USA
3Calgary Animal Referral and Emergency Centre, 12th Street Southeast, Calgary, AB, Canada T2H 2Y4

Received 22 January 2011; Accepted 29 March 2011

Academic Editor: Michael Stoskopf

Copyright © 2011 Diane V .H. Hendrix et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. Berger, R. H. Scagliotti, and E. M. Lund, “A quantitative study of the effects of tribrissen on canine tear production,” Journal of the American Animal Hospital Association, vol. 31, no. 3, pp. 236–241, 1995. View at Google Scholar · View at Scopus
  2. R. V. Morgan and A. J. Bachrach, “Keratoconjunctivitis sicca associated with sulfonamide therapy in dogs,” Journal of the American Veterinary Medical Association, vol. 180, no. 4, pp. 432–434, 1982. View at Google Scholar · View at Scopus
  3. G. Klauss, E. A. Giuliano, C. P. Moore et al., “Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992–2002),” Journal of the American Veterinary Medical Association, vol. 230, no. 4, pp. 541–547, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. R. Hollingsworth, D. D. Canton, N. C. Buyukmihci, and T. B. Farver, “Effect of topically administered atropine on tear production in dogs,” Journal of the American Veterinary Medical Association, vol. 200, no. 10, pp. 1481–1484, 1992. View at Google Scholar · View at Scopus
  5. I. P. Herring, J. P. Pickett, E. S. Champagne, and M. Marini, “Evaluation of aqueous tear production in dogs following general anesthesia,” Journal of the American Animal Hospital Association, vol. 36, no. 5, pp. 427–430, 2000. View at Google Scholar · View at Scopus
  6. T. J. Kern and H. N. Erb, “Facial neuropathy in dogs and cats: 95 cases (1975–1985),” Journal of the American Veterinary Medical Association, vol. 191, no. 12, pp. 1604–1609, 1987. View at Google Scholar · View at Scopus
  7. R. Carter and C. M. H. Colitz, “The causes, diagnosis, and treatment of canine keratoconjunctivitis sicca,” Veterinary Medicine, vol. 97, no. 9, pp. 683–694, 2002. View at Google Scholar · View at Scopus
  8. B. H. Grahn and L. S. Sandmeyer, “Diseases and surgery of the canine nasolacrimal system,” in Veterinary Ophthalmology, K. N. Gelatt, Ed., pp. 618–661, Blackwell Publishing, 2007. View at Google Scholar
  9. R. V. Morgan, J. M. Duddy, and K. Mcclurg, “Prolapse of the gland of the third eyelid in dogs: a retrospective study of 89 cases (1980–1990),” Journal of the American Animal Hospital Association, vol. 29, no. 1, pp. 56–60, 1993. View at Google Scholar
  10. H. D. Westermeyer, D. A. Ward, and K. Abrams, “Breed predisposition to congenital alacrima in dogs,” Veterinary Ophthalmology, vol. 12, no. 1, pp. 1–5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. R. L. Kaswan, C. L. Martin, and W. L. J. Chapman, “Keratoconjunctivitis sicca: histopathologic study of nictitating membrane and lacrimal glands from 28 dogs,” American Journal of Veterinary Research, vol. 45, no. 1, pp. 112–118, 1984. View at Google Scholar · View at Scopus
  12. D. I. Bounous, K. P. Carmichael, R. L. Kaswan, S. Hirsh, and J. Stiles, “Effects of ophthalmic cyclosporine on lacrimal gland pathology and function in dogs with keratoconjunctivitis sicca,” Veterinary and Comparative Ophthalmology, vol. 5, no. 1, pp. 5–12, 1995. View at Google Scholar
  13. R. L. Kaswan, M. A. Salisbury, and D. A. Ward, “Spontaneous canine keratoconjunctivitis sicca: a useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops,” Archives of Ophthalmology, vol. 107, no. 8, pp. 1210–1216, 1989. View at Google Scholar · View at Scopus
  14. M. A. Salisbury, R. L. Kaswan, D. A. Ward, C. L. Martin, J. M. Ramsey, and C. A. Fischer, “Topical application of cyclosporine in the management of keratoconjunctivitis sicca in dogs,” Journal of the American Animal Hospital Association, vol. 26, no. 3, pp. 269–274, 1990. View at Google Scholar · View at Scopus
  15. D. K. Olivero, M. G. Davidson, R. V. English, M. P. Nasisse, V. E. Jamieson, and T. M. Gerig, “Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs,” Journal of the American Veterinary Medical Association, vol. 199, no. 8, pp. 1039–1042, 1991. View at Google Scholar · View at Scopus
  16. R. V. Morgan and K. L. Abrams, “Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs,” Journal of the American Veterinary Medical Association, vol. 199, no. 8, pp. 1043–1046, 1991. View at Google Scholar · View at Scopus
  17. C. P. Moore, J. B. Mchugh, J. G. Thorne, and T. E. Phillips, “Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model,” Investigative Ophthalmology and Visual Science, vol. 42, no. 3, pp. 653–659, 2001. View at Google Scholar · View at Scopus
  18. C. Izci, I. Celik, F. Alkan et al., “Histologic characteristics and local cellular immunity of the gland of the third eyelid after topical ophthalmic administration of 2% cyclosporine for treatment of dogs with keratoconjunctivitis sicca,” American Journal of Veterinary Research, vol. 63, no. 5, pp. 688–694, 2002. View at Google Scholar · View at Scopus
  19. R. Ofri, G. N. Lambrou, I. Allgoewer et al., “Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine a,” Veterinary Journal, vol. 179, no. 1, pp. 70–77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. B. C. Gilger, J. Andrews, D. A. Wilkie et al., “Cellular immunity in dogs with keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine,” Veterinary Immunology and Immunopathology, vol. 49, no. 3, pp. 199–208, 1995. View at Google Scholar
  21. B. C. Gilger, J. Andrews, D. A, Wilkie et al., “Lymphocyte proliferation and blood drug levels in dogs with keratoconjunctivitis sicca receiving long-term topical ocular cyclosporine,” and Comparative Ophthalmology, vol. 6, no. 2, pp. 125–130, 1996. View at Google Scholar
  22. D. L. Williams, “Lack of effects on lymphocyte function from chronic topical ocular cyclosporine medication: a prospective study,” Veterinary Ophthalmology, vol. 13, no. 5, pp. 315–320, 2010. View at Google Scholar
  23. A. Berdoulay, R. V. English, and B. Nadelstein, “Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca,” Veterinary Ophthalmology, vol. 8, no. 4, pp. 225–232, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Anglade, R. Yatscoff, R. Foster, and U. Grau, “Next-generation calcineurin inhibitors for ophthalmic indications,” Expert Opinion on Investigational Drugs, vol. 16, no. 10, pp. 1525–1540, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. U. Benelli, A. Lepri, M. Del Tacca, and M. Nardi, “FK-506 delays corneal graft rejection in a model of corneal xenotransplantation,” Journal of Ocular Pharmacology and Therapeutics, vol. 12, no. 4, pp. 425–431, 1996. View at Google Scholar · View at Scopus
  26. A. W. Thomson, C. A. Bonham, and A. Zeevi, “Mode of action of tacrolimus (FK506): molecular and cellular mechanisms,” Therapeutic Drug Monitoring, vol. 17, no. 6, pp. 584–591, 1995. View at Google Scholar · View at Scopus
  27. US Food and Drug Administration, “Public health advisory: Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment,” US Food and Drug Administration, Rockville, Md, USA, 2005, http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/UCM051760.
  28. S. L. Schreiber and G. R. Crabtree, “The mechanism of action of cyclosporin A and FK506,” Immunology Today, vol. 13, no. 4, pp. 136–142, 1992. View at Google Scholar · View at Scopus